A first-in-class EGFR-directed KRAS G12V selective inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• KRAS G12V is a prevalent oncogenic mutation lacking approved direct inhibitors.
• RNA interference (RNAi) therapies face challenges in cancer treatment, including targeting specificity and stability.
• Targeted delivery platforms using modified siRNAs offer potential solutions to overcome RNAi limitations.

Purpose of the Study:

• To develop and evaluate an EGFR-directed RNAi molecule (EFTX-G12V) for selective KRAS G12V targeting.
• To assess the therapeutic efficacy of EFTX-G12V in preclinical cancer models.
• To investigate the potential of targeted RNAi for oncogene silencing and cancer therapy.

Main Methods:

• Design of a chemically modified siRNA conjugated to an EGFR-targeting ligand (EFTX-G12V).
• In vitro and in vivo evaluation of EFTX-G12V's selectivity and anti-cancer activity.
• Assessment of tumor silencing of KRAS G12V and inhibition of cancer hallmarks.

Main Results:

• EFTX-G12V demonstrated high selectivity for KRAS G12V, outperforming pan-KRAS targeting.
• Targeted RNAi delivery achieved effective KRAS G12V tumor silencing.
• Significant anti-tumor activity was observed across multiple cancer models.

Conclusions:

• EGFR-directed RNAi represents a technological advancement for oncogene targeting.
• Targeted RNAi delivery of EFTX-G12V shows significant therapeutic potential for KRAS G12V-driven cancers.
• These findings offer new insights into KRAS targeting, with implications for improved cancer therapy safety and efficacy.